MADRIGAL PHARMACEUTICALS, INC. (MDGL) Operating Margin
- Operating margin · 12 months: Value -25.13%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -25.13% | Operating income / revenue. Period ending 2026-06-30. $-322.62M ÷ $1.28B × 100 ≈ -25.13% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -322.62M USD | Operating Income (Loss) |
| Revenue | 1.28B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | (m) | |
| Selling, general and administration | 1.01B USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-322.62M | $1.28B | (m) | (m) | $1.01B | -25.13% |
| 2026-03-31 | $-313.51M | $1.13B | (m) | (m) | $914.47M | -27.68% |
| 2025-12-31 | $-300.10M | $958.40M | (m) | (m) | $813.83M | -31.31% |
| 2025-09-30 | $-307.48M | $740.64M | (m) | (m) | $715.07M | -41.52% |
| 2025-06-30 | $-309.81M | $515.55M | (m) | (m) | $613.54M | -60.09% |
| 2025-03-31 | $-425.15M | $317.38M | $10.75M | (m) | $522.13M | -133.95% |
| 2024-12-31 | $-497.88M | $180.13M | $6.23M | (m) | $435.06M | -276.39% |
| 2024-09-30 | $-548.05M | $76.81M | (m) | (m) | (m) | -713.49% |
| 2024-06-30 | $-530.28M | $14.64M | (m) | (m) | (m) | -3622.66% |
| 2024-03-31 | $-454.20M | $0.00 | (m) | (m) | (m) | (m) |
| 2023-12-31 | $-380.50M | $0.00 | (m) | (m) | (m) | (m) |
| 2023-09-30 | $-348.62M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $-330.50M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $-314.32M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $-293.57M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $-272.87M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $-255.62M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $-247.09M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $-242.48M | $0.00 | (m) | (m) | (m) | (m) |
| 2021-09-30 | $-237.44M | $0.00 | (m) | (m) | (m) | (m) |
| 2021-06-30 | $-233.06M | $0.00 | (m) | (m) | (m) | (m) |
| 2021-03-31 | $-221.65M | $0.00 | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-206.67M | $0.00 | (m) | (m) | (m) | (m) |
| 2020-09-30 | $-177.07M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $-142.48M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $-114.86M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-94.97M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $-79.47M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $-66.61M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $-51.73M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-40.68M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $-35.14M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $-32.44M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $-33.06M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-32.06M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $-30.91M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $-36.36M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $-30.56M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $-25.22M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $-82.76M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $-37.71M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $-53.73M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $-67.61M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $-77.12M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $-79.18M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $-81.38M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $-83.95M | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | $-87.50M | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | $-89.85M | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | $-90.21M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-87.56M | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | $-81.82M | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | $-74.56M | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | $-66.63M | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $-60.94M | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | $-53.48M | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | $-51.16M | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | $-49.03M | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $-45.43M | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-36.90M | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $79.30M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |